pharma · Esophageal Cancer · Esophageal Squamous Cell Carcinoma
Shanghai SIMR Biotech
Shanghai Chest Hospital
Shanghai Chest Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Esophageal Cancer, Esophageal Squamous Cell Carcinoma, NSCLC. NovaPharmaNews links 3 clinical program(s), 0 dr
Shanghai, CN HQ
2014 Founded
23 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Founded
- 2014
- Employees
- 23
- Programs
- 3
- Drugs
- 14
- Patents
- 0
neoadjuvant anti-PD-1
Phase 2 · small molecule · Esophageal Cancer
neoadjuvant anti-PD-1 for Esophageal Cancer is a Phase 2 program (small_molecule) at Shanghai Chest Hospital with 1 ClinicalTrials.gov record(s).
Internal code SCE2401
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Chest Hospital
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Esophageal Cancer
- Status
- active
- Trials
- 1